

The Molecular Targeting of Glioblastoma: Drug Discovery and Therapies

Guest Editor:

Dr. Mayra Paolillo

Department of Drug Sciences,
University of Pavia, Pavia, Italy

Deadline for manuscript
submissions:

closed (25 July 2021)

Message from the Guest Editor


Dear Colleagues,

Among the most lethal cancer types, glioblastoma still holds a prominent position and represents a tremendous challenge for physicians, patients and scientists. A number of therapeutic strategies have been developed, but results, in terms of life expectancy, are far from the desired objectives. For this reason, the research for new molecular targets is increasingly pressing. Gene amplification, mutation and methylation represent research fields in glioblastoma that continuously provide new perspectives for therapy. Additionally, molecular targeting by integrin receptors has, in recent years, given rise to new hopes. This Special Issue of the *Journal of Personalized Medicine* aims to cover the current most advanced therapies, with a particular focus on the discovery of new potential molecular targets and related forthcoming therapies. Special attention will be devoted to the experimental models currently used in drug discovery and to their potential application in glioblastoma research.

Dr. Mayra Paolillo

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)